{"name":"Agios Pharmaceuticals, Inc.","slug":"agios","ticker":"AGIO","exchange":"NASDAQ","domain":"agios.com","description":"Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment ","hq":"Cambridge, MA","founded":0,"employees":"539","ceo":"Brian Goff","sector":"Rare Disease","stockPrice":28.8,"stockChange":0.03,"stockChangePercent":0.1,"marketCap":"$1.7B","metrics":{"revenue":66048000,"revenueGrowth":137.7,"grossMargin":0,"rdSpend":339535000,"netIncome":-412781000,"cash":737038016,"dividendYield":0,"peRatio":-6.3,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Tibsovo patent cliff ($1.1B at risk)","drug":"Tibsovo","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Tibsovo patent cliff ($1.1B at risk)","drug":"Tibsovo","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"oncology","drugs":[{"name":"AG-181","genericName":"AG-181","slug":"ag-181","indication":"Other","status":"phase_1"},{"name":"AG-236","genericName":"AG-236","slug":"ag-236","indication":"Other","status":"phase_1"},{"name":"AG-348 Sequence A","genericName":"AG-348 Sequence A","slug":"ag-348-sequence-a","indication":"Other","status":"phase_1"},{"name":"AG-348 Sequence B","genericName":"AG-348 Sequence B","slug":"ag-348-sequence-b","indication":"Other","status":"phase_1"},{"name":"AG-946","genericName":"AG-946","slug":"ag-946","indication":"Other","status":"phase_1"},{"name":"AG881 Formulation 1","genericName":"AG881 Formulation 1","slug":"ag881-formulation-1","indication":"Other","status":"phase_1"},{"name":"AG881 Formulation 2","genericName":"AG881 Formulation 2","slug":"ag881-formulation-2","indication":"Other","status":"phase_1"},{"name":"[13C6]AG-348","genericName":"[13C6]AG-348","slug":"13c6-ag-348","indication":"Other","status":"phase_1"},{"name":"[14C]-AG-120","genericName":"[14C]-AG-120","slug":"14c-ag-120","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"AG120","genericName":"AG120","slug":"ag120","indication":"Acute myeloid leukemia (AML) with isocitrate dehydrogenase 1 (IDH1) mutation","status":"phase_1"},{"name":"AG-881","genericName":"AG-881","slug":"ag-881","indication":"Acute myeloid leukemia (AML)","status":"phase_1"},{"name":"AG221","genericName":"AG221","slug":"ag221","indication":"Acute myeloid leukemia","status":"phase_1"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"AG-348","genericName":"AG-348","slug":"ag-348","indication":"Pyruvate kinase deficiency","status":"phase_3"},{"name":"Placebo Matching Mitapivat","genericName":"Placebo Matching Mitapivat","slug":"placebo-matching-mitapivat","indication":"Pyruvate kinase deficiency","status":"phase_3"}]}],"pipeline":[{"name":"AG-181","genericName":"AG-181","slug":"ag-181","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AG120","genericName":"AG120","slug":"ag120","phase":"phase_1","mechanism":"Inhibits mutant IDH1 enzyme","indications":["Acute myeloid leukemia (AML) with isocitrate dehydrogenase 1 (IDH1) mutation"],"catalyst":""},{"name":"AG-236","genericName":"AG-236","slug":"ag-236","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AG-348","genericName":"AG-348","slug":"ag-348","phase":"phase_3","mechanism":"AG-348 activates pyruvate kinase R (PKR), an enzyme that increases ATP production in red blood cells to improve their survival and reduce hemolysis.","indications":["Pyruvate kinase deficiency","Sickle cell disease"],"catalyst":""},{"name":"AG-348 Sequence A","genericName":"AG-348 Sequence A","slug":"ag-348-sequence-a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AG-348 Sequence B","genericName":"AG-348 Sequence B","slug":"ag-348-sequence-b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AG-881","genericName":"AG-881","slug":"ag-881","phase":"phase_1","mechanism":"Tet methylcytosine dioxygenase 2 (TET2) inhibitor","indications":["Acute myeloid leukemia (AML)"],"catalyst":""},{"name":"AG-946","genericName":"AG-946","slug":"ag-946","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AG221","genericName":"AG221","slug":"ag221","phase":"phase_1","mechanism":"IDH2 inhibitor","indications":["Acute myeloid leukemia"],"catalyst":""},{"name":"AG881 Formulation 1","genericName":"AG881 Formulation 1","slug":"ag881-formulation-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AG881 Formulation 2","genericName":"AG881 Formulation 2","slug":"ag881-formulation-2","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo Matching Mitapivat","genericName":"Placebo Matching Mitapivat","slug":"placebo-matching-mitapivat","phase":"phase_3","mechanism":"Mitapivat activates pyruvate kinase R (PKR), an enzyme that increases ATP production in red blood cells to improve their survival and function.","indications":["Pyruvate kinase deficiency","Sickle cell disease"],"catalyst":""},{"name":"[13C6]AG-348","genericName":"[13C6]AG-348","slug":"13c6-ag-348","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[14C]-AG-120","genericName":"[14C]-AG-120","slug":"14c-ag-120","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-02-28","type":"earnings","headline":"Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"Agios Pharmaceuticals reported its fourth quarter and full year 2022 financial results, with revenue of $143.4 million and a net loss of $143.4 million.","drugName":"","sentiment":"neutral"},{"date":"2022-12-16","type":"deal","headline":"Agios Pharmaceuticals Announces Collaboration with Novartis to Develop and Commercialize Pyruvate Kinase Deficiency Treatment","summary":"Agios Pharmaceuticals announced a collaboration with Novartis to develop and commercialize its pyruvate kinase deficiency treatment.","drugName":"","sentiment":"positive"},{"date":"2022-08-09","type":"regulatory","headline":"FDA Grants Orphan Drug Designation to Agios' Pyruvate Kinase Deficiency Treatment","summary":"The FDA granted orphan drug designation to Agios' pyruvate kinase deficiency treatment.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxPaTRTQjRFalJ6LVp3NFI2Qm1YOXB1SktTenhfV3pYak9OaTllcWtadVdpaWI0MzZodW1iVEgxNG03TXEyUlZNamk1eU1UUVMtQVQ1U2MwWkxCNkNnUzZWZHpqVkpOSGpyUEkyM2QtSGJnejZHdnFmdHFoMU1TVGFWV0dEZXpLNktRbjlaNDRzODRZaTFWd3FoaC11RnpGWTJSYW03SGl6cU9uSGZQYi1kNXdGSW9FQl85N2FLWE83U1owOWF1MUNRWW9KdXZWdw?oc=5","date":"2026-04-01","type":"pipeline","source":"Finviz","summary":"Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky - Finviz","headline":"Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxObnlRZjlVdldSekZURTdVOVdSY3pXclY4emI1Mzd4cXI0QVRJOXVnM1NXY1lxaDlGb2lDUFRmN2tmNmNEZUxybjJ2N0o4WEt2Q2pOMVhrOUV5S01LS1Rzek9lRllZQzNzeFItbWt6VnNfN1UtQXRuVmVGUk9RM0lkNElyVjhwd0k?oc=5","date":"2026-01-19","type":"pipeline","source":"Finviz","summary":"Agios Pharmaceuticals, Inc. (AGIO): A Bull Case Theory - Finviz","headline":"Agios Pharmaceuticals, Inc. (AGIO): A Bull Case Theory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxOci1TRlVXa0RvbEpfbkVKVW5sVFViUk1XX0RCcTVnZjBFcDdNcjMzZzVZWHlhdkItTF85bkxyWFp5emlUM2pLQU1wdHl6Q2Z3akpBOGM2UWxQZ21wZGlfLXJlc1FLX01mOTY2UVZnLTljLTRrZThjM2hxRDBoeWR2SzROZ09sUmdvR2JPa2ZKWVhIandQVHJLLVlJVUMteUUyejNhTlNESHgtY3czRzMzUjFXbWJQUUxZc3ZhTEQ4N0sybEFNNEVlNGs2ZGdQWWVVRk1aTEM5M0huaDRta3RzVXdR?oc=5","date":"2025-12-24","type":"regulatory","source":"reuters.com","summary":"Agios Pharma shares jump as US FDA expands approval for blood disorder drug - reuters.com","headline":"Agios Pharma shares jump as US FDA expands approval for blood disorder drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOaG40SE1KOVpoMXZSeE82azg0bkxJTy1DSjliUm5YOHRNYUVBQ3JYZUFGXy1BT0xMaDNyenFoajhhbXZHSENOYWM3MUk4Vjh5WTl2dTY1R2ozbHVsZFhDVHJZQXFIdTlsTUllMHJabXVPVC1kTEVSSVhpWUdGOWJpZmhidlc3VWs0WUdGM2NnZGl1ZFQx?oc=5","date":"2025-12-24","type":"regulatory","source":"Seeking Alpha","summary":"Agios Pharma Stock: A Buy After FDA Approves Aqvesme (NASDAQ:AGIO) - Seeking Alpha","headline":"Agios Pharma Stock: A Buy After FDA Approves Aqvesme (NASDAQ:AGIO)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQZmIyNkszV1JQTVlhV2FZSEZSNGFpNzVEM2pXUkRwSjZOcjYwS2htX2x3YjdDcDAxQkhCRnR2Qnh6NEpPSVpXX0lwZ2xjMHJKcVBCNVJtUVJ6ajc5ODIzZjdGdWc5dDh6SDlESmU1Q3oxbHdnamRBbDZ4YnJDb1pvdjI5ZzBtREF3MkpTYk9DV2ljUDlqTzlraUQ2a0h2RlRwaVdvYVR3MkNJWHpqNU1Ed2pyeDFiZDlVVlM5dmFlVXdqVXpyWWJR?oc=5","date":"2025-11-25","type":"pipeline","source":"Investing.com","summary":"Cantor Fitzgerald reiterates Overweight rating on Agios Pharma stock - Investing.com","headline":"Cantor Fitzgerald reiterates Overweight rating on Agios Pharma stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQVlhIWHl6eV8yRkVFUG13X2d4aWUtdlV4d1RKUVVGMGs2MXZXZjQyYWQxem85YnZUcFpveWlrVS1ERVhSUmJ3ZHNCSUlScW4yN2lYNWRTSW9ka0JHUzRnZkU0SXJjN2FrMXVITzVQaGwzWHFSeEJzYXVsRC1aOXcxcTMtQmZVcElFdU52TjA5R3NhUG1jNTVUSUl3ajA3TVR4NUR0RkdaWG5Ea1RVeEI3UFpTUXdhMjBDSlRTVFVn?oc=5","date":"2025-11-19","type":"regulatory","source":"Seeking Alpha","summary":"Agios Pharma: Study Fail May Affect Mitapivat TDT Approval - Expect More Volatility - Seeking Alpha","headline":"Agios Pharma: Study Fail May Affect Mitapivat TDT Approval - Expect More Volatility","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOVzhQV1NVTnJTN015bDZaNXlZQVBlZVhoMGo3YnJJbzJoa0NPQS1sZzgwOWhNOHVlS2JQdnpzY1pBendzYUVsb0N1UF9MNkZkRVR2N1FKODRTU1hKWDBHTGJzcWpfVlFjSTZvNHFQZGt4SFV0dFdCTHViOGlQTERuOERmTVV4ZllVWGdSXzBHME16XzJ6NnhYeGwydmpQR0FfYTNn?oc=5","date":"2025-11-19","type":"pipeline","source":"Investor's Business Daily","summary":"This Biotech Just Lost Half Its Value As Its Rival Celebrated - Investor's Business Daily","headline":"This Biotech Just Lost Half Its Value As Its Rival Celebrated - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxPTVZ5R0t4dVRIWldOanU5bFdBb1V1Y2ZMa2tDa2pMT1otTE01RHJIQTZCYWxLTW9EMUZVVXFEZlNtaExlcEdYMEV4amFyaXRiWXIyWmktT2FXWk9rZ1QxTDF5OFVCUG5yWWJ4WXE2TzU0V0JxSTA5d2lwVE1NU0VLU0lfb0RPNTJtdGQwNXpRcGhCZFJlbWJBbzFIY1hoQ2JqNlJQZFVDRHE3SkZnbElSMkVFallKREhwQ2huWXNhdVFRQzJDOWJ6cTJuclhreDd3a09tM3VwUDJZaW9adFJCb3NlY1pEY0Rxbllj?oc=5","date":"2025-11-19","type":"trial","source":"Stocktwits","summary":"AGIO Stock Cracks After Sickle-Cell Disease Drug Delivers Mixed Results In Late-Stage Trial - Stocktwits","headline":"AGIO Stock Cracks After Sickle-Cell Disease Drug Delivers Mixed Results In Late-Stage Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQMXlIRllYMGVEYWI0M1lGNFg4empoaTltdlJMOUMyc2pfVzRDbGRGdjI1Z1I1bndqZkFaclVyT29EWDljaGIxMjBVcGlTUm9rck51Yi1KY01UN3NiQ0VsYU4taExFYXBiTUVJRnFBWkRGWjVSZ0UxbGZMUjBqVG1fVFF5ZlI1TjRONG01TWhQMmVLU0VGYjVpbXBtcC0?oc=5","date":"2025-09-07","type":"regulatory","source":"RTTNews","summary":"Biotech Stocks Facing FDA Decision In September 2025 - RTTNews","headline":"Biotech Stocks Facing FDA Decision In September 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOOWZpWUJlUHA0ZEZuSU5GeHl0NkFmT3FmTDdMVDF5bGVUcS12cmxIT01WNWdGME4wWlFkTkdrOWh4ajRKZXpMZ1ZTcllSQmktS0ZIWkpWc2VudlEtVWZmWmFZaTVzV1BoMWVxakdGMy14dUIwTHYzQzQ5X0Q1T1A4WUFJaFJmbktndWRfdHRwSkgwTGQ3V1drcnFlakRyNzRGdkhRNXZqelVrY2VMQzRNNVFIUGhsMTU0aU55b2JzQQ?oc=5","date":"2025-09-04","type":"regulatory","source":"Seeking Alpha","summary":"Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated - Seeking Alpha","headline":"Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPN3FOTnNTMzMwTlZWbmtVdWxYOTFkaEpZaFFIRlpGUmY2dmc5cjJiY1ZkaFQ3QVJPdTZLZFU5Rmp5OXNNSnl5MjRHdU1TbS1TNFZZWEFsNlpTSUNTbDBCWENDdzBBUHBjRGNnNDZhUjByQ0hKU2tKSlYxMVFNRmE3bHZRTC1GdDE3VkE?oc=5","date":"2025-02-12","type":"pipeline","source":"Yahoo Finance","summary":"Agios Pharmaceuticals, Inc. (AGIO): A Cheap Biotech Stock to Invest In Now - Yahoo Finance","headline":"Agios Pharmaceuticals, Inc. (AGIO): A Cheap Biotech Stock to Invest In Now","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE5XWTUxTDRNSlFQR2F4b3pVRWtnZF9IMUFRQUdLczZaWmpoUDd6dnRqVG1mUXVnS0tBUWdHQ2xzVUxpLVdZTEtHREJkWGhUT19m?oc=5","date":"2024-02-28","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[{"drugName":"Tibsovo","drugSlug":"ivosidenib","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1100000000}],"drugCount":14,"phaseCounts":{"phase_1":12,"phase_3":2},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Celgene","Novartis","Gilead Sciences"],"therapeuticFocus":["Rare Genetic Diseases","Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":30013000,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":30013000,"period":"2018-12-31"},{"value":15198000,"period":"2018-09-30"},{"value":40414000,"period":"2018-06-30"},{"value":8762000,"period":"2018-03-31"},{"value":43011000,"period":"2017-12-31"}],"grossProfit":47683000,"grossProfitHistory":[{"period":"2025-12-31","value":47683000},{"period":"2024-12-31","value":32333000},{"period":"2023-12-31","value":23942000},{"period":"2022-12-31","value":12536000}],"rdSpend":339535000,"rdSpendHistory":[{"period":"2025-12-31","value":339535000},{"period":"2024-12-31","value":301286000},{"period":"2023-12-31","value":295526000},{"period":"2022-12-31","value":279910000}],"sgaSpend":180280000,"operatingIncome":-472132000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-472132000},{"period":"2024-12-31","value":-425737000},{"period":"2023-12-31","value":-391487000},{"period":"2022-12-31","value":-389047000}],"netIncome":-412781000,"netIncomeHistory":[{"period":"2025-12-31","value":-412781000},{"period":"2024-12-31","value":673725000},{"period":"2023-12-31","value":-352088000},{"period":"2022-12-31","value":-231801000}],"eps":-7.12,"epsHistory":[{"period":"2025-12-31","value":-7.12},{"period":"2024-12-31","value":11.64},{"period":"2023-12-31","value":-6.33},{"period":"2022-12-31","value":-4.23}],"cash":89130000,"cashHistory":[{"period":"2025-12-31","value":89130000},{"period":"2024-12-31","value":76247000},{"period":"2023-12-31","value":88205000},{"period":"2022-12-31","value":139259000}],"totalAssets":1297225000,"totalLiabilities":104111000,"totalDebt":40207000,"equity":1193114000,"operatingCashflow":-372977000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-372977000},{"period":"2024-12-31","value":-389841000},{"period":"2023-12-31","value":-296062000},{"period":"2022-12-31","value":-309478000}],"capex":-14316000,"capexHistory":[{"period":"2025-12-31","value":-14316000},{"period":"2024-12-31","value":-1685000},{"period":"2023-12-31","value":-18499000},{"period":"2022-12-31","value":-4881000}],"freeCashflow":-387293000,"dividendsPaid":null,"buybacks":0,"employees":539,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":48304000,"ebit":-110025000,"ebitda":-108662000,"period":"2026-03-31","revenue":20746000,"epsBasic":-1.69,"netIncome":-99111000,"rdExpense":81148000,"epsDiluted":-1.69,"grossProfit":19427000,"operatingIncome":-110025000},{"sga":51610000,"ebit":-121578000,"ebitda":-120312000,"period":"2025-12-31","revenue":19967000,"epsBasic":null,"netIncome":-108039000,"rdExpense":88056000,"epsDiluted":null,"grossProfit":18088000,"operatingIncome":-121578000},{"sga":41274000,"ebit":-116869000,"ebitda":-115495000,"period":"2025-09-30","revenue":12880000,"epsBasic":-1.78,"netIncome":-103433000,"rdExpense":86796000,"epsDiluted":-1.78,"grossProfit":11201000,"operatingIncome":-116869000},{"sga":45869000,"ebit":-127056000,"ebitda":-125797000,"period":"2025-06-30","revenue":12455000,"epsBasic":-1.93,"netIncome":-112020000,"rdExpense":91940000,"epsDiluted":null,"grossProfit":10753000,"operatingIncome":-127056000},{"sga":41527000,"ebit":-106629000,"ebitda":-105351000,"period":"2025-03-31","revenue":8726000,"epsBasic":-1.55,"netIncome":-89289000,"rdExpense":72743000,"epsDiluted":-1.55,"grossProfit":7641000,"operatingIncome":-106629000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":16.65,"netIncome":null,"rdExpense":null,"epsDiluted":16.22,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":28.8,"previousClose":28.77,"fiftyTwoWeekHigh":46,"fiftyTwoWeekLow":22.24,"fiftyTwoWeekRange":"22.24 - 46.0","fiftyDayAverage":29.42,"twoHundredDayAverage":32.74,"beta":0.58,"enterpriseValue":1009705216,"forwardPE":-6.3,"priceToBook":1.54,"priceToSales":25.93,"enterpriseToRevenue":15.29,"enterpriseToEbitda":-2.15,"pegRatio":0,"ebitda":-470265984,"ebitdaMargin":0,"freeCashflow":-267222000,"operatingCashflow":-380408000,"totalDebt":35745000,"debtToEquity":3.2,"currentRatio":14.19,"returnOnAssets":-21.7,"returnOnEquity":-32.8,"analystRating":"1.6 - Buy","recommendationKey":"buy","numberOfAnalysts":8,"targetMeanPrice":41.12,"targetHighPrice":60,"targetLowPrice":28,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.1,"institutionHeldPercent":109.2,"sharesOutstanding":59471609,"floatShares":50618665,"sharesShort":6974194,"shortRatio":4.81,"shortPercentOfFloat":11.7,"epsTrailing":-7.26,"epsForward":-4.6,"revenuePerShare":1.13,"bookValue":18.69,"officers":[{"age":56,"name":"Mr. Brian M. Goff M.B.A.","title":"CEO & Director"},{"age":50,"name":"Ms. Cecilia  Jones","title":"Chief Financial Officer"},{"age":47,"name":"Mr. James William Burns","title":"Chief Legal Officer"},{"age":46,"name":"Dr. Krishnan  Viswanadhan M.B.A., Pharm.D.","title":"Chief Corporate Development & Strategy Officer"},{"age":45,"name":"Dr. Sarah  Gheuens M.D., Ph.D.","title":"Chief Medical Officer and Head of Research & Development"},{"age":76,"name":"Dr. Lewis clayton Cantley Ph.D.","title":"Co-Founder"},{"age":79,"name":"Dr. Tak Wah Mak D.Sc., FRSC, Ph.D.","title":"Co-Founder"},{"age":72,"name":"Dr. Craig B. Thompson M.D.","title":"Co-Founder"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.agios.com","phone":"617 649 8600"}}